Form 4: Arcus Biosciences CAO Executes Planned Stock Sale
Statement of Changes in Beneficial Ownership
Chief Accounting Officer Alexander Azoy sold 2,562 shares of Arcus Biosciences common stock via a Rule 10b5-1 trading plan.
Summary
- Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, sold 2,562 shares of common stock on June 1, 2026.
- The shares were sold at a weighted average price of $25.7704 per share, with individual transaction prices ranging from $25.67 to $25.90.
- The transaction was executed pursuant to a pre-established Rule 10b5-1 trading plan.
- The shares sold were acquired through the company's Employee Stock Purchase Plan on May 29, 2026.
- Following the transaction, the reporting person retains beneficial ownership of 39,581 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement and represents a small portion of the officer's total holdings.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.
Negatives
- The transaction represents a divestment of equity by a key member of the financial leadership team.
Risks
- Market volatility could impact the value of remaining holdings for the reporting person.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and generally does not signal a change in corporate strategy or outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact expected on shareholders as the sale was pre-planned and relatively small in volume.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Date shares were purchased through the Employee Stock Purchase Plan. |
| 06/01/2026 | Date of the reported stock sale transaction. |
Keywords
Arcus Biosciences, RCUS, Insider Trading, Form 4, Chief Accounting Officer, Equity Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.